RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

How to identify, manage patients with high-risk ulcerative colitis

by dtrubin | November 5, 2019 | In the Press, Presentations, UC | 0 Comments

Dr. Rubin discusses his presentation at ACG 2019 in San Antonio on identifying and managing patients with high-risk ulcerative colitis with Healio Gastroenterology. “The importance of knowing who is high risk has to do with your choices of treatment and your...

‘We’ve Moved the Needle Quite Far’ in Management of Crohn Disease

by dtrubin | November 27, 2018 | CD, In the Press, therapies | 0 Comments

Dr. Rubin discusses how the management of Crohn disease has changed over time, the importance of understanding the disease for proper management, and common mistakes in treatment that remain.

Dr. David T. Rubin Summarizes His Presentation from the Advances in Inflammatory Bowel Diseases Conference on Preparing for IBD Care in the Next Pandemic

by nmgarcia | December 13, 2021 | In the Press | 0 Comments

Click here for the full video of Dr. Rubin detailing his 8-point strategy for steps the gastroenterology community should take to prepare for another pandemic in the future to ensure the best outcomes for patients and conditions for professionals.

Dr. David T. Rubin on Bowel Urgency: the Next Frontier in Management of Ulcerative Colitis

by David Rubin | October 19, 2023 | In the Press | 0 Comments

Listen here as Professor David T. Rubin discusses bowel urgency in ulcerative colitis and its management with Professor Laurent Peyrin-Biroulet in a recent episode of IBDscope.

IBD Drive Time Podcast: Ethical Issues in Clinical Trials

by David Rubin | October 19, 2023 | In the Press | 0 Comments

Take a listen to the third episode of a four-part series wherein Professor Rubin guest-hosts the Gastroenterology Learning Network's IBD Drive Time and discusses the ethics of clinical trials in IBD, as well as challenges to recruitment, alongside Professor Severine...

Dr. David T. Rubin Summarizes His Presentation from Digestive Diseases Week on Advancing Therapies and the Field of IBD

by David Rubin | June 7, 2023 | In the Press | 0 Comments

Click here to listen to Dr. Rubin discuss the importance of head-to-head and comparative trials, combination therapies, optimization with timing, escalation and de-escalation, and how we should approach new therapies.

Hospital-stay duration after IBD surgery not linked to sleep, activity

by dtrubin | December 16, 2019 | biosensor, In the Press | 0 Comments

Second-year Pritzker medical student, Yangtian Yi, received Best Abstract in Surgery at AIBD 2019 for his abstract associating length of stay for IBD surgical patients with data collected from wearable devices. His oral presentation and abstract was reported on by...

U.S. News & World Report features Dr. Rubin in “What’s the Difference Between Colitis and Crohn’s Disease?”

by dtrubin | March 20, 2019 | CD, In the Press, UC | 0 Comments

“A distinguishing feature of ulcerative colitis is that it's confined to the large intestine, which encompasses your colon and rectum, says Dr. David Rubin, chief of gastroenterology and a professor of medicine with University of Chicago Medicine....

Should You Scale Back on Your UC Treatment?

by zfine | May 28, 2025 | In the Press | 0 Comments

A provocative new paper proposes that less could be more for some people when it comes to drug therapy for IBD. https://www.healthcentral.com/news/ulcerative-colitis/should-you-scale-back-on-your-uc-treatment

Dr. Rubin Taps in on “IBD Community Throwing Elbows Over Value of TDM” in Gastroenterology and Endoscopy News

by dtrubin | August 14, 2019 | In the Press, monitoring, therapies | 0 Comments

Dr. Mark Silverberg, Dr. David T Rubin, Dr. Laura Targownik, and Dr. Charabaty excitingly discuss why IBD specialists are divided on the topic of therapeutic drug monitoring (TDM). “If the drug is going to work but isn’t present in the body, it doesn’t do its job,”...